Arcus Biosciences, Inc.
RCUS· NYSE
Released Feb 21, 2024, after the close
10-K filed Feb 21, 2024, 52 days after period end · 0001724521-24-000052
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $31.00M | — | $354.62M | $9.49M |
| Net Income | -$81.00M | -$67.00M |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| $279.54M |
| -$51.85M |
| EPS Diluted | — | — | — | -$0.82 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.